Skip to main content
SpringerLink
Log in

Current lymphoma diagnostic standards: the pathologists’ view

  • review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

This short review aims at summarizing the current standards of lymphoma diagnostics and some novelties in the recent WHO classification. The importance of close collaboration between clinicians and pathologists to render the correct diagnosis and to find the most appropriate treatment for each individual patient is highlighted. In lymphomas, the diagnostic evaluation of histopathology, immune phenotype and genetics are puzzle pieces that have to be put into a broader context with the help of the information given by the clinical colleagues, such as patient’s age and sex, location of the lesion, previous medical history and medication. An excision of the affected lymph node is always preferable to fine needle biopsies, as—in many instances—only the evaluation of the whole specimen allows for reliable diagnosis, grading and additional investigations.

The new WHO classification entailed many changes in the category of diffuse large B‑cell lymphoma and high-grade B‑cell lymphoma. The obligatory specification of the cell of origin in diffuse large B‑cell lymphoma is obtained via additional immunohistochemical stainings. The identification of high-grade B‑cell lymphomas with genetic double/triple hits, requiring a more aggressive management, can only be achieved by the detection of chromosomal translocations (MYC, BCL2 and/or BCL6). Significant changes in the classification of T‑cell lymphomas have occurred due to the recognition of the follicular T‑helper cell origin in some instances, and sharpening diagnostic borders of intestinal T‑cell- and Epstein-Barr-virus-associated proliferations. Finally, the discovery of disease-defining and/or prognostically relevant mutations makes the introduction of proper routine molecular testing mandatory.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. US lymphoid malignancy statistics by World Health Organization subtypes. Ca Cancer J Clin. 2016; https://doi.org/10.3322/caac.21357.

    Article  PubMed  Google Scholar 

  2. Schinasi L, Leon ME. Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis. Int J Environ Res Public Health. 2014;11(4):4449–527.

    Article  Google Scholar 

  3. Tzankov A, Dirnhofer S. A pattern-based approach to reactive lymphadenopathies. Semin Diagn Pathol. 2018;35(1):4–19.

    Article  Google Scholar 

  4. Ansell SM, Armitage JO. Positron emission tomographic scans in lymphoma: convention and controversy. Mayo Clin Proc. 2012;87(6):571–80.

    Article  Google Scholar 

  5. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2017.

    Google Scholar 

  6. Attarbaschi A, Beishuizen A, Mann G, Rosolen A, Mori T, Uyttebroeck A, et al. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a “watch and wait” strategy after complete resection. Ann Hematol. 2013;92(11):1537–41.

    Article  CAS  Google Scholar 

  7. Louissaint A Jr., Schafernak KT, Geyer JT, Kovach AE, Ghandi M, Gratzinger D, et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood. 2016;128(8):1093–100.

    Article  CAS  Google Scholar 

  8. Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, Szczepanowski M, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B‑cell lymphoma affecting predominantly children and young adults. Blood. 2011;118(1):139–47.

    Article  CAS  Google Scholar 

  9. Copie-Bergman C, Niedobitek G, Mangham DC, Selves J, Baloch K, Diss TC, et al. Epstein-Barr virus in B‑cell lymphomas associated with chronic suppurative inflammation. J Pathol. 1997;183(3):287–92.

    Article  CAS  Google Scholar 

  10. Cheuk W, Chan AC, Chan JK, Lau GT, Chan VN, Yiu HH. Metallic implant-associated lymphoma: a distinct subgroup of large B‑cell lymphoma related to pyothorax-associated lymphoma? Am J Surg Pathol. 2005;29(6):832–6.

    Article  Google Scholar 

  11. Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014;32(2):114–20.

    Article  Google Scholar 

  12. Fong D, Steurer M, Greil R, Gunsilius E, Spizzo G, Gastl G, et al. Hodgkin lymphoma in Tyrol—a population-based study. Ann Hematol. 2009;88(5):449–56.

    Article  Google Scholar 

  13. Menter T, Juskevicius D, Alikian M, Steiger J, Dirnhofer S, Tzankov A, et al. Mutational landscape of B‑cell post-transplant lymphoproliferative disorders. Br J Haematol. 2017;178(1):48–56.

    Article  CAS  Google Scholar 

  14. DeStefano CB, Desai SH, Shenoy AG, Catlett JP. Management of post-transplant lymphoproliferative disorders. Br J Haematol. 2018; https://doi.org/10.1111/bjh.15263.

    Article  PubMed  Google Scholar 

  15. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B‑cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.

    Article  CAS  Google Scholar 

  16. Gutiérrez-García G, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, Mate JL, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B‑cell lymphoma treated with immunochemotherapy. Blood. 2011;117(18):4836–43.

    Article  Google Scholar 

  17. Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B‑cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200–7.

    Article  Google Scholar 

  18. Lunning MA, Vose JM. Angioimmunoblastic T‑cell lymphoma: the many-faced lymphoma. Blood. 2017;129(9):1095–102.

    Article  CAS  Google Scholar 

  19. Weiss LM, Chen YY. EBER in situ hybridization for Epstein-Barr virus. Methods Mol Biol. 2013;999:223–30.

    Article  CAS  Google Scholar 

  20. Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015;170(4):504–14.

    Article  Google Scholar 

  21. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, et al. Double-hit B‑cell lymphomas. Blood. 2011;117(8):2319–31.

    Article  CAS  Google Scholar 

  22. Hoeller S, Tzankov A, Stenner F, Dirnhofer S. When and how to test for C‑MYC in aggressive B cell lymphomas. J Hematop. 2015;8(1):13–20.

    Article  Google Scholar 

  23. Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B‑cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014;27(7):958–71.

    Article  CAS  Google Scholar 

  24. Swerdlow SH, Kuzu I, Dogan A, Dirnhofer S, Chan JK, Sander B, et al. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch. 2016;468(3):259–75.

    Article  CAS  Google Scholar 

  25. Wang YL. MYD88 mutations and sensitivity to Ibrutinib therapy. J Mol Diagn. 2018;20(2):264–6.

    Article  Google Scholar 

  26. Turakhia S, Lanigan C, Hamadeh F, Swerdlow SH, Tubbs RR, Cook JR. Immunohistochemistry for BRAF V600E in the differential diagnosis of hairy cell leukemia vs other splenic B‑cell lymphomas. Am J Clin Pathol. 2015;144(1):87–93.

    Article  CAS  Google Scholar 

  27. Pettirossi V, Santi A, Imperi E, Russo G, Pucciarini A, Bigerna B, et al. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood. 2015;125(8):1207–16.

    Article  CAS  Google Scholar 

  28. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B‑cell leukemias. Blood. 1995;85(6):1580–9.

    CAS  PubMed  Google Scholar 

  29. Buccheri V, Barreto WG, Fogliatto LM, Capra M, Marchiani M, Rocha V. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation. Ann Hematol. 2018;97(12):2269–78.

    Article  CAS  Google Scholar 

  30. Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016;127(17):2122–30.

    Article  CAS  Google Scholar 

  31. Bottoni A, Rizzotto L, Lai TH, Liu C, Smith LL, Mantel R, et al. Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood. 2016;128(26):3101–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Obermann EC, Mueller N, Rufle A, Menter T, Mueller-Garamvoelgyi E, Cathomas G, et al. Clonal relationship of classical Hodgkin lymphoma and its recurrences. Clin Cancer Res. 2011;17(16):5268–74.

    Article  CAS  Google Scholar 

  33. Juskevicius D, Lorber T, Gsponer J, Perrina V, Ruiz C, Stenner-Liewen F, et al. Distinct genetic evolution patterns of relapsing diffuse large B‑cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis. Leukemia. 2016;30(12):2385–95.

    Article  CAS  Google Scholar 

  34. Montoto S. Treatment of patients with transformed lymphoma. Hematology Am Soc Hematol Educ Program. 2015;2015:625–30.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pathology and Medical Genetics, University Hospital Basel, Schönbeinstrasse 40, 4031, Basel, Switzerland

    Magdalena M. Gerlach &  Alexandar Tzankov

Authors
  1. Magdalena M. Gerlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexandar Tzankov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandar Tzankov.

Ethics declarations

Conflict of interest

M.M. Gerlach and A. Tzankov declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gerlach, M.M., Tzankov, A. Current lymphoma diagnostic standards: the pathologists’ view. memo 12, 17–23 (2019). https://doi.org/10.1007/s12254-019-0472-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-019-0472-y

Keywords

Search

Navigation